Belumosudil for Chronic Graft-Versus-Host Disease: Analysis of Long-Term Results from the KD025-208 and ROCKstar Studies

期限(时间) 移植物抗宿主病 寄主(生物学) 医学 疾病 生物 内科学 遗传学 物理 量子力学
作者
S J Lee,Steven Z. Pavletic,Bruce R. Blazar,Yu Yao,Ran Ji,Kathy Marshall,Corey Cutler
出处
期刊: [Elsevier BV]
卷期号:31 (7): 434.e1-434.e10
标识
DOI:10.1016/j.jtct.2025.04.020
摘要

Belumosudil is an oral selective rho-associated coiled-coil-containing protein kinase-2 (ROCK2) inhibitor approved for the treatment of chronic graft-versus-host disease (cGVHD) following an allogeneic hematopoietic cell transplant in patients aged ≥12 years after failure of ≥2 prior systemic lines of therapy. The KD025-208 (NCT02841995) and KD025-213 (ROCKstar; NCT03640481) studies demonstrated that belumosudil was well tolerated, with clinically meaningful responses in patients with cGVHD. KD025-217 (NCT05305989) is a follow-up study that evaluated extended treatment with belumosudil in patients enrolled in the parent studies, KD025-208 and ROCKstar. This pooled analysis reports the long-term follow-up (overall median follow-up duration of 31.4 months) results from these studies in patients with cGVHD. The study included a total of 208 patients across 3 cohorts. Cohort 1 (n = 95) received belumosudil 200 mg once daily, cohort 2 (n = 92) received belumosudil 200 mg twice daily, and cohort 3 (n = 21) received belumosudil 400 mg once daily. The primary endpoint was best overall response rate (ORR). Duration of response (DOR), failure-free survival (FFS), and time to next treatment (TTNT) were also evaluated in this analysis. The best ORR in the modified intent-to-treat (mITT) population was 72%. The median DOR for the responder population was 62.3 weeks (range, 36.1 to 82.6 weeks). The median FFS in the mITT population was 15.1 months (range, 11.3 to 20.6 months). The 1- and 2-year FFS rates were 56% and 40%, respectively. The median TTNT was 22.1 months (range, 15.2 to 40.3 months), where 47% of patients received a new systemic therapy for cGVHD by 36 months. When compared with the published data, the long-term results from this pooled analysis of these two phase 2 studies demonstrated belumosudil was associated with durable responses, and it remained well tolerated with no new safety concerns.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
福星高照完成签到 ,获得积分10
刚刚
大家好完成签到 ,获得积分10
刚刚
cwp发布了新的文献求助10
刚刚
1秒前
莫筱铭完成签到,获得积分10
1秒前
kk完成签到,获得积分10
1秒前
禄禄完成签到 ,获得积分10
1秒前
小李科研完成签到 ,获得积分10
1秒前
福风完成签到,获得积分10
2秒前
2秒前
睽阔完成签到 ,获得积分10
2秒前
共享精神的应助被qwert采纳,获得10
2秒前
科研狗完成签到,获得积分0
2秒前
2秒前
企鹅不耐热完成签到,获得积分10
3秒前
杨媛发布了新的文献求助10
3秒前
JH_发布了新的文献求助10
3秒前
BINGBONG完成签到,获得积分10
3秒前
坦率的橘子完成签到,获得积分10
4秒前
辛勤的硬币完成签到,获得积分20
4秒前
4秒前
细胞核完成签到,获得积分10
4秒前
菠萝星猫发布了新的文献求助10
5秒前
5秒前
冲就完了发布了新的文献求助10
5秒前
lyl完成签到 ,获得积分10
5秒前
Yolotto3完成签到,获得积分10
5秒前
幸福黄蜂完成签到 ,获得积分10
5秒前
周xj完成签到,获得积分10
5秒前
pineapple完成签到 ,获得积分10
5秒前
英姑的应助被便便民工采纳,获得10
5秒前
剑兰先生完成签到,获得积分10
6秒前
6秒前
Stitch完成签到,获得积分10
6秒前
犹豫的冰香完成签到,获得积分10
6秒前
MingQue完成签到,获得积分10
7秒前
daigang发布了新的文献求助10
7秒前
李晓彤发布了新的文献求助10
7秒前
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180488
求助须知:如何正确求助?哪些是违规求助? 9570437
关于积分的说明 21812406
捐赠科研通 7776516
什么是DOI,文献DOI怎么找? 3433277
关于科研通互助平台的介绍 2557516
邀请新用户注册赠送积分活动 2479162